Stroke patients treated intravenously with loberamisal, a novel neuroprotective medication, daily for 10 days and starting ...

Late-Breaking Science Abstract LB 032 - In a phase III clinical trial in China, stroke patients treated intravenously with loberamisal, a novel neuroprotective medication, daily for 10 days starting ...

Bradley Page suffered a stroke on the highway near Casa Grande. The cops who responded made things worse, he says.

NEW ORLEANS -- Loberamisal improved functional outcomes after acute ischemic stroke in a placebo-controlled phase III trial, ...

With the study adding to a mix of conflicting trial results, it’s not yet time to update guidelines, Shyam Prabhakaran says.

As stroke systems of care evolve, clinicians are increasingly torn between the known safety of traditional, aggressive ...

For patients with noncardioembolic ischemic stroke or high-risk transient ischemic attack, asundexian, a factor XIa inhibitor ...

Experts at ISC 2026 highlighted growing evidence that GLP-1 receptor agonists may reduce stroke risk and support brain health through anti-inflammatory, vascular, and neuroprotective mechanisms.

A new predictive tool may help identify patients at risk for poststroke dementia, potentially accelerating research and ...

Adults hospitalized with an acute respiratory syncytial virus (RSV) infection faced an increased risk of cardiorespiratory events such as heart attack or stroke in the weeks afterward, according to a ...

Though recombinant factor VIIa didn’t improve outcomes overall, treating very early and in those with a spot sign on CT may ...